In this study, relapsing patients showed a positivity for CD326+ and CD26+/CD326− CTCs even when the primary cancer had a low pathological grade, suggesting that CTCs can identify high-risk colorectal cancer patients at early stages. This evidence concerns the gene EPCAM and cancer.